Netter-2, Lutetium Lu 177 For Well-Differentiated Net

NETTER-2, Lutetium Lu 177 for well-differentiated NET

OncBrothers: Practice-Changing Cancer Discussions

NETTER-2: 177Lu-DOTATATE in gastroenteropancreatic NETs

Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains

177Lu-DOTATATE in patients with well-differentiated, high-grade NETs

NETTER-1 update: 177Lu-DOTATATE in patients with midgut neuroendocrine tumors

Dr. Strosberg on the Results of the NETTER-1 Trial

June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study

Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs

GI ASCO 2024 Highlights with Dr. Pamela Kunz – CheckMate 8HW, EMERALD-1, NETTER-2

OncBrothers: Practice-Changing Cancer Discussions

April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study

Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors

Targeted Oncology

day2 ksnmmi 2013 - 19 Lu 177 Therapy in Neuroendocrine Tumor

PRRT Therapy by Dr. Ishita B Sen | Nuclear Medicine Therapy

Nuclear Medicine Therapy

Clinical Nuclear Medicine | PRRT, Lutathera and NETTER 1 trial

Dr. Philip on Adverse Events With Lutathera in NETs

Dr. Philip Discusses the Use of Lutathera in NETs

NETTER-1: Radioactive Octreotide Effective in Metastatic Neuroendocrine Tumors

Rare Disease Report

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC • Dr. Aman Chauhan

02 - New Treatments and Trials: Radioligand Therapy/ PPRT by Dr. Courtney Lawhn Heath

Radioisotopic Targeting of NETs: Lutetium-177 Dotatate and What Does the Future Hold? by Dr.Bushnell

Neuroendocrine Cancer Awareness Network (NCAN)